Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The contribution of attention-deficit/hyperactivity disorder polygenic load to metabolic and cardiovascular health outcomes: a large-scale population and sibling study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Emerging evidence suggests that ADHD is associated with increased risk for metabolic and cardiovascular (cardiometabolic) diseases. However, an understanding of the mechanisms underlying these associations is still limited. In this study we estimated the associations of polygenic scores (PGS) for ADHD with several cardiometabolic diseases and biomarkers. Furthermore, we investigated to what extent the PGS effect was influenced by direct and indirect genetic effects (i.e., shared familial effects). We derived ADHD-PGS in 50,768 individuals aged 18–90 years from the Dutch Lifelines Cohort study. Using generalised estimating equations, we estimated the association of PGS with cardiometabolic diseases, derived from self-report and several biomarkers measured during a physical examination. We additionally ran within-sibling PGS analyses, using fixed effects models, to disentangle direct effects of individuals’ own ADHD genetic risk from confounding due to indirect genetic effects of relatives, as well as population stratification. We found that higher ADHD-PGS were statistically significantly associated with several cardiometabolic diseases (R-squared [R 2] range = 0.03–0.50%) and biomarkers (related to inflammation, blood pressure, lipid metabolism, amongst others) (R 2 range = 0.01–0.16%) ( P < 0.05). Adjustment for shared familial factors attenuated the associations between ADHD-PGS and cardiometabolic outcomes (on average 56% effect size reduction), and significant associations only remained for metabolic disease. Overall our findings suggest that increased genetic liability for ADHD confers a small but significant risk increase for cardiometabolic health outcomes in adulthood. These associations were observable in the general population, even in individuals without ADHD diagnosis, and were partly explained by familial factors shared among siblings.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A global reference for human genetic variation

          The 1000 Genomes Project set out to provide a comprehensive description of common human genetic variation by applying whole-genome sequencing to a diverse set of individuals from multiple populations. Here we report completion of the project, having reconstructed the genomes of 2,504 individuals from 26 populations using a combination of low-coverage whole-genome sequencing, deep exome sequencing, and dense microarray genotyping. We characterized a broad spectrum of genetic variation, in total over 88 million variants (84.7 million single nucleotide polymorphisms (SNPs), 3.6 million short insertions/deletions (indels), and 60,000 structural variants), all phased onto high-quality haplotypes. This resource includes >99% of SNP variants with a frequency of >1% for a variety of ancestries. We describe the distribution of genetic variation across the global sample, and discuss the implications for common disease studies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

            Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019. Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% UI: 93.2 to 111 million) prevalent cases of stroke in 2019. Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality due to noncommunicable diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents.

              The literature on the prevalence of mental disorders affecting children and adolescents has expanded significantly over the last three decades around the world. Despite the field having matured significantly, there has been no meta-analysis to calculate a worldwide-pooled prevalence and to empirically assess the sources of heterogeneity of estimates.
                Bookmark

                Author and article information

                Contributors
                ebba.du.rietz@ki.se
                Journal
                Transl Psychiatry
                Transl Psychiatry
                Translational Psychiatry
                Nature Publishing Group UK (London )
                2158-3188
                13 November 2024
                13 November 2024
                2024
                : 14
                : 470
                Affiliations
                [1 ]Department of Medical Epidemiology and Biostatistics, Karolinska Institute, ( https://ror.org/056d84691) Stockholm, Sweden
                [2 ]GRID grid.4830.f, ISNI 0000 0004 0407 1981, Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), Department of Psychiatry, , University Medical Center Groningen, University of Groningen, ; Groningen, The Netherlands
                [3 ]GRID grid.4494.d, ISNI 0000 0000 9558 4598, Department of Epidemiology, University of Groningen, , University Medical Center Groningen, ; Groningen, The Netherlands
                [4 ]PROMENTA Research Center, Department of Psychology, University of Oslo, ( https://ror.org/01xtthb56) Oslo, Norway
                [5 ]School of Medical Sciences, Faculty of Medicine and Health, Örebro University, ( https://ror.org/05kytsw45) Örebro, Sweden
                [6 ]Shenzhen Center for Chronic Disease Control, ( https://ror.org/05h3xe829) Shenzhen, Guangdong China
                Author information
                http://orcid.org/0000-0002-3427-0792
                http://orcid.org/0000-0003-2442-7941
                http://orcid.org/0000-0003-2574-990X
                http://orcid.org/0000-0002-4811-2330
                http://orcid.org/0000-0002-4777-6338
                http://orcid.org/0000-0003-1949-2298
                http://orcid.org/0000-0002-8094-8859
                Article
                3178
                10.1038/s41398-024-03178-2
                11561358
                39537628
                19a52cf2-3ee1-4371-aa0f-2ef0cc25aa0b
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 17 November 2023
                : 14 October 2024
                : 5 November 2024
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100003748, Svenska Sällskapet för Medicinsk Forskning (Swedish Society for Medical Research);
                Award ID: PD20-0036
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100003186, Fredrik och Ingrid Thurings Stiftelse (Fredrik and Ingrid Thurings Foundation);
                Award ID: 2021-00638
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100005416, Norges Forskningsråd (Research Council of Norway);
                Award ID: 288083
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100004359, Vetenskapsrådet (Swedish Research Council);
                Award ID: 2018-02599
                Award ID: 2022-01119
                Award Recipient :
                Categories
                Article
                Custom metadata
                © Springer Nature Limited 2024

                Clinical Psychology & Psychiatry
                adhd,genomics
                Clinical Psychology & Psychiatry
                adhd, genomics

                Comments

                Comment on this article